Drug Trial Radar · NCT02782741
Study to Compare the Efficacy and Safety of Enzyme Replacement Therapies Avalglucosidase Alfa and Alglucosidase Alfa Administered Every Other Week in Patients With Late-onset Pompe Disease Who Have Not Been Previously Treated for Pompe Disease
Last checked: Nov 20, 2026Latest source record: Apr 4, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
101
Actual
Start
Nov 2, 2016
Primary completion
Mar 19, 2020
Study completion May 31, 2023
Sponsor
- Lead sponsor
- Genzyme, a Sanofi CompanySanofi (SNY)
- Sponsor type
- Industry
- First posted
- May 25, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 3 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Primary Objective: To determine the effect of avalglucosidase alfa treatment on respiratory muscle strength measured by percent (%) predicted forced vital capacity (FVC) in the upright position, as compared to alglucosidase alfa. Secondary Objective: To determine the safety and effect of avalglucosidase alfa treatment on functional endurance (6-minute walk test, inspiratory muscle strength (maximum inspiratory pressure), expiratory muscle strength (maximum expiratory pressure), lower extremity muscle strength (hand-held dynamometry), motor function (Quick Motor Function Test), and health-related quality of life (Short Form-12).
Conditions
- Glycogen Storage Disease Type II;Pompe's Disease
Interventions
Avalglucosidase alfa (GZ402666)Drug
Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
Alglucosidase alfa (GZ419829)Drug
Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous
Primary outcomes
What the sponsor says the trial is designed to measure.
- PAP: Change From Baseline in Percent Predicted FVC in Upright Position at Week 49Time frame: Baseline, Week 49
Locations
69 sites in 25 countries. Site status is shown where the registry gives one.
Investigational Site Number 8400015
Phoenix, Arizona
Investigational Site Number 8400020
Los Angeles, California
Investigational Site Number 8400011
Orange, California
Investigational Site Number 8400017
Stanford, California
Investigational Site Number 8400016
Gainesville, Florida
Investigational Site Number 8400007
Decatur, Georgia
Investigational Site Number 8400023
Chicago, Illinois
Investigational Site Number 8400002
Iowa City, Iowa
Investigational Site Number 8400012
Kansas City, Kansas
Investigational Site Number 8400010
Boston, Massachusetts
Investigational Site Number 8400001
Detroit, Michigan
Investigational Site Number 8400019
Minneapolis, Minnesota
Investigational Site Number 8400026
Great Neck, New York
Investigational Site Number 8400008
Valhalla, New York
Investigational Site Number 8400006
Durham, North Carolina
Investigational Site Number 8400009
Cincinnati, Ohio
Investigational Site Number 8400014
Portland, Oregon
Investigational Site Number 8400025
Pittsburgh, Pennsylvania
Investigational Site Number 8400018
Salt Lake City, Utah
Investigational Site Number 8400005
Fairfax, Virginia
Investigational Site Number 8400024
Morgantown, West Virginia
Investigational Site Number 0320001
Caba, Argentina
Investigational Site Number 0360001
Auchenflower, Australia
Investigational Site Number 0400001
Vienna, Austria
Investigational Site Number 0560003
Brussels, Belgium
Investigational Site Number 0560001
Leuven, Belgium
Investigational Site Number 0760004
Brasília, Brazil
Investigational Site Number 0760001
São Paulo, Brazil
Investigational Site Number 1240003
Hamilton, Canada
Investigational Site Number 1240002
Montreal, Canada
Investigational Site Number 2030001
Prague, Czechia
Investigational Site Number 2080003
København Ø, Denmark
Investigational Site Number 2500008
Angers, France
Investigational Site Number 2500007
Bordeaux, France
Investigational Site Number 2500011
Brest, France
Investigational Site Number 2500004
Bron, France
Investigational Site Number 2500010
Clermont-Ferrand, France
Investigational Site Number 2500005
Lille, France
Investigational Site Number 2500006
Marseille, France
Investigational Site Number 2500001
Paris, France
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.